Former President and Chief Executive Officer · Spyre Therapeutics, Inc. (SYRE)

Jeffrey Goldberg

A named executive officer of Spyre Therapeutics in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$830,207

Salary $248,471Stock awards $0

FY2022: $1,832,485

5th of 5 named executive officers at Spyre Therapeutics by FY2023 total.

5 named officers on file for Spyre Therapeutics, FY2023

Jeffrey Goldberg’s pay file — $29

  • 2 fiscal years of pay, line by line
  • SYRE’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Spyre Therapeutics’s whole pay program stands against its peers

  • Spyre Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SYRE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 1, 2024 (DEF 14A).

Free

Get Jeffrey Goldberg’s full pay file as a PDF — free

More than this page: up to 10 years of Jeffrey’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Jeffrey Goldberg compensation by year

Spyre Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Spyre Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$54,616$248,471
Bonus$0$0
Stock awards$0$0
Option awards$1,774,952$0
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$2,917$581,736
Total$1,832,485$830,207

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Spyre Therapeutics, Inc. DEF 14A filed April 1, 2024, accession 0001636282-24-000021, and prior-year filings.

How this page was built: the Spyre Therapeutics, Inc. filed document, accession 0001636282-24-000021. Every figure is read from that document and cited to the page and table it appears in. Filed April 1, 2024.

$1.8M
$830K
FY22
FY23
SalaryOption awardsAll other

Spyre Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Cameron TurtleChief Executive Officer$15,919,545
Jonathan AlspaughFormer Chief Financial Officer$8,360,029
Scott BurrowsChief Financial Officer$7,551,539
Heidy King-JonesChief Legal Officer and Corporate Secretary$6,588,281
Jeffrey Goldberg · this pageFormer President and Chief Executive Officer$830,207

The full Spyre Therapeutics compensation record

free company brief

This page is one person within Spyre Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Spyre Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Spyre Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jeffrey Goldberg's compensation dossier · One-time report. No refunds.